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Catheter-Based Renal Sympathetic Denervation for
Resistant Hypertension
Durability of Blood Pressure Reduction Out to 24 Months
Symplicity HTN-1 Investigators*
Abstract—Renal sympathetic hyperactivity is seminal in the maintenance and progression of hypertension. Catheter-based
renal sympathetic denervation has been shown to significantly reduce blood pressure (BP) in patients with hypertension.
Durability of effect beyond 1 year using this novel technique has never been reported. A cohort of 45 patients with
resistant hypertension (systolic BP160 mm Hg on3 antihypertension drugs, including a diuretic) has been originally
published. Herein, we report longer-term follow-up data on these and a larger group of similar patients subsequently
treated with catheter-based renal denervation in a nonrandomized manner. We treated 153 patients with catheter-based
renal sympathetic denervation at 19 centers in Australia, Europe, and the United States. Mean age was 5711 years,
39% were women, 31% were diabetic, and 22% had coronary artery disease. Baseline values included mean office BP
of 176/9817/15 mm Hg, mean of 5 antihypertension medications, and an estimated glomerular filtration rate of 8320
mL/min per 1.73 m2. The median time from first to last radiofrequency energy ablation was 38 minutes. The procedure
was without complication in 97% of patients (149 of 153). The 4 acute procedural complications included 3 groin
pseudoaneurysms and 1 renal artery dissection, all managed without further sequelae. Postprocedure office BPs were
reduced by 20/10, 24/11, 25/11, 23/11, 26/14, and 32/14 mm Hg at 1, 3, 6, 12, 18, and 24 months, respectively. In conclusion,
in patients with resistant hypertension, catheter-based renal sympathetic denervation results in a substantial reduction in
BP sustained out to 2 years of follow-up, without significant adverse events. (Hypertension. 2011;57:911-917.)
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Hypertension remains a major global public health bur-den, affecting more than a quarter of adults in developed
societies.1 It is the leading attributable cause of mortality
worldwide, causing 7.5 million deaths annually. Every 20/
10-mm Hg increase in blood pressure (BP) is associated with
a doubling of cardiovascular mortality.2,3 Epidemiological
studies have shown that awareness of the condition is poor,
with approximately half of hypertensives adequately treated
to target BP levels.4–6 Furthermore, among patients with
hypertension, there exists a subgroup who are unable to
achieve adequate BP control despite the use of multiple
medications and dietary and lifestyle modifications. These
patients (termed “refractory” or “resistant”) are, by common
definition, receiving 3 different classes of antihypertensive
therapy, with 1 being a diuretic, and at maximal recom-
mended or maximal tolerated doses.7
Among such patients, treatment options are few. Addi-
tional pharmacological strategies have been proposed. Device
or procedure-based therapies have also been studied recently.
One such approach involves a percutaneous, catheter-based
renal sympathetic denervation procedure to disrupt renal
afferent and efferent nerves using radiofrequency ablation.
Initial proof-of-concept studies have demonstrated both re-
ductions in BP (out to 12 months), as well as evidence of
organ-specific sympathetic denervation. Furthermore, the
procedure was found to be both simple to perform and safe
(minimal procedure-related adverse events).8,9 Recently a
randomized, controlled clinical trial of renal denervation in
patients with treatment-resistant hypertension showed a 33/
11-mm Hg reduction of 6-month office BP compared with
control.9
An outstanding question with regard to renal denervation
in general and the radiofrequency approach taken in particu-
lar is the durability of the BP-lowering effect. This is because
efferent nerves have been demonstrated to anatomically
regrow over a period of months to years without consistent
demonstration of functional reinnervation.10,11 Therefore, it is
of great interest and importance to evaluate the long-term
safety and the durability of BP reduction that may follow the
denervation procedure. Accordingly, the aim of the present
analysis was to examine long-term outcomes among the
entire initial cohort of refractory hypertension patients who
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underwent the nonrandomized, open-label, catheter-based
renal denervation procedure.
Methods
Study Setting
This open-label, proof-of-concept study enrolled 153 patients at 19
investigational sites in Australia, Europe, and the United States
between June 6, 2007, and May 1, 2010. Ethics committees at each
site approved the study, and written informed consent was obtained
from all of the patients.
Patient Population
Patients were enrolled based on having an elevated office systolic BP
(160 mm Hg) despite taking3 antihypertensive drug classes, 1 of
which was a diuretic, at target or maximal tolerated dose. Patients
were excluded if they had an estimated glomerular filtration rate
(eGFR) of 45 mL/min per 1.73 m2, type 1 diabetes mellitus or a
known secondary cause of hypertension other than sleep apnea or
chronic kidney disease. Patients with significant renovascular abnor-
malities were not permitted to undergo the intervention. This was
assessed by various methods, including angiography, magnetic
resonance angiography, computed tomography angiography, and
duplex ultrasound. Such anatomic abnormalities included multiple
main renal arteries, short length main renal artery, and hemodynam-
ically significant renal artery stenosis. Patients had to be 18 years
of age.
Study Procedures and Assessments
The primary efficacy end point of the study was change in office BP.
Patients had office BP measurements performed in accordance with
Joint National Committee VII guidelines.3 Measurements were
performed sitting, in triplicate, and then averaged. The primary
safety assessments were based on physical examination, basic blood
chemistries, and anatomic assessment of the renal vasculature. Renal
evaluations were performed via angiography in initial patients (at 14
to 30 days after procedure) and via renal magnetic resonance
angiography, computed tomography angiography, or duplex scan at
6 months.
Physicians could alter background BP-lowering medication at any
time for clinical reasons but were encouraged not to do so unless
considered absolutely necessary, to carefully assess the effect of the
procedure, per se. This was more strictly applied during the initial 12
months of the follow-up study and less so after this time.
Baseline measurements included physical examination, vital
signs, basic blood chemistries, and pregnancy testing as appropriate.
Follow-up assessments occurred at 1, 3, 6, 12, 18, and 24 months.
Assessment of routine biochemistry, including eGFR (using the
Modification of Diet in Renal Disease formula), was performed
within the individual laboratories of participating hospitals.
Renal Denervation Procedure
The denervation procedure itself involves an endovascular catheter-
based approach to disrupt renal sympathetic nerves using radiofre-
quency (RF) ablation applied via an electrode at the catheter tip. The
central arterial tree is accessed via the femoral artery. The lumen of
the main renal artery is catheterized using a 6F or 8F guide. The
Symplicity Catheter (Ardian, Inc) is connected to an RF generator,
and multiple RF treatments are applied in a manner devised to
maximize renal sympathetic nerve disruption within the individual
artery. Specifically, the first RF treatment is applied distally in the
renal artery, and the catheter is then retracted by 5 mm and rotated
circumferentially before the energy is reapplied. This is continued
until 4 to 6 treatments have been applied within each renal artery and
across the full circumference of the vessel. Each low-power treat-
ment lasts 2 minutes.
As described in the initial report of this open-label experience, the
first 10 patients underwent staged sequential procedures involving a
single renal artery followed by the contralateral artery 1 month later.
Subsequent patients underwent bilateral procedures in the 1 session.8
Statistical Analysis
BP levels from baseline to the above time points were evaluated to
calculate mean change, as well as 95% CIs. This was assessed by
repeated-measures ANOVA with pairwise comparison of significant
values. A 2-tailed paired t test of P0.05 was regarded as statisti-
cally significant. Multivariate stepwise backward regression analysis
of key demographic and procedural characteristics that may predict
increased systolic BP response was performed. Baseline variables
entered into the model were age, sex, race, body mass index, systolic
BP, diastolic BP, pulse pressure, heart rate, drug class, number of
antihypertensive medications, eGFR, hypercholesterolemia, and cor-
onary artery disease. Change in eGFR was evaluated in comparison
with baseline at various time points using the paired t test. All of the
statistical analysis was performed using SPSS version 15.0.
Results
Patient Characteristics
We treated 153 patients in this open-label, proof-of-concept
study. Baseline characteristics of the study subjects including
demographics and background medication are listed in Tables
1 and 2. Mean baseline BP values were 176/9817/
14 mm Hg. Patients were taking an average of 5.11.4
antihypertensive drug classes.
Procedure Characteristics
A 6F guide was used in 55 patients and an 8F guide in 98
patients. The median time from first to last RF energy
Table 1. Demographics of Treated Patients
Variables Data
AgeSD, y 5711
Sex (female) 39%
Ethnic origin (non-white) 5%
Type 2 diabetes mellitus 31%
CAD 22%
Hyperlipidemia 68%
eGFR, mL/min per 1.73 m2 8320
Heart rate, bpm 7313
Blood pressure, mm Hg 176/9817/15
CAD indicates coronary artery disease; eGFR, estimated glomerular filtration
rate.
Table 2. Baseline Antihypertensive Medications and
Antihypertensive Medications at Last Available Follow-Up
Antihypertensive Medications
Baseline
(n153)
Last Available
Follow-Up (n151)
No. of antihypertension medications 5.11.4 5.01.5
Diuretic 95% 92%
Aldosterone blocker 22% 24%
ACE inhibitor or ARB 91% 92%
Direct renin inhibitor 14% 13%
-blocker 82% 82%
Calcium-channel blocker 75% 72%
Centrally acting sympatholytic 33% 32%
Vasodilator 19% 15%
-1 blocker 19% 19%
ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor
blocker.
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delivery was 38 minutes, with an average of 4 ablations in
each renal artery. There were no device malfunctions. Con-
scious sedation using IV narcotics and anxiolytics were
commonly used to prevent and manage expected pain during
the procedure. Episodes of bradycardia observed during the
procedure were managed with administration of atropine in
10% patients (15 of 153 patients).
Efficacy
BP-Lowering Efficacy
Ninety-two percent of patients had an office BP reduction of
10 mm Hg. Within-patient changes in both systolic and
diastolic BPs were highly significant (P0.0001 for all
systolic and diastolic changes except 24-month diastolic BP,
where P0.002) at all time points postprocedure with BPs
reduced on average by 20/10, 24/11, 25/11, 23/11, 26/14, and
32/14 mm Hg at 1, 3, 6, 12, 18, and 24 months, respectively
(Figure 1A). When patient BP values were censored for
medication increases postprocedure, there was little change in
BP values over time compared with the uncensored values
(Figure 1B). Similarly, when BP values over time were
analyzed for the 18 patients who had data out to 2 years
(Figure 1C), there was, again, little change in BP values
compared with the uncensored values. Figure 2 illustrates the
distribution of BP levels at baseline preprocedure and at 12
and 24 months postprocedure.
Baseline Predictors of BP Response
Significant independent predictors of greater systolic BP
response on multivariate analysis were higher baseline sys-
tolic BP (P0.0001) and use of central sympatholytic agents
(P0.018). All of the other baseline parameters fell out as
nonsignificant on multivariate analysis.
Antihypertensive Medication Changes Postprocedure
The number of antihypertensive medications at last available
follow-up was unchanged as compared with baseline (5.0
versus 5.1; P0.11). In addition, classes of antihypertensive
drugs were similar to baseline at last available follow-up
(Table 2). Twenty-seven patients were on a reduced number
of medications at last follow-up compared with baseline; 18
were on increased medications. Of the 18 patients with
medication increases, 10 had their medications increased after
drops in BP, presumably in an attempt to achieve additional
reductions in BP. To ascertain the BP-lowering effect of renal
denervation in the absence of increased medications, office
BP data censored after an increase in the number of medica-
tions is presented in Figure 1B. The magnitude of the mean
BP reduction in response to the procedure was unchanged
when data from patients with increased antihypertension
medications were censored.
Safety
Periprocedural Safety
The procedure was without complication in 97% of patients
(149 of 153 patients). One patient experienced the renal artery
dissection on placement of the treatment catheter before RF
energy delivery was delivered in that artery. The dissection
was treated with renal artery stenting without any subsequent
complication or delay in hospital discharge. Three other
patients developed a pseudoaneurysm/hematoma in the fem-
oral access site; all had had an 8F guide and were treated
without any subsequent complication. In all of the cases, the
procedure was performed with standard techniques for fem-
oral artery access using commercially available introducers.
Renal Vascular Safety
As mentioned, follow-up renal artery imaging was performed to
evaluate structural abnormalities that may have occurred post-
procedure in the treated renal arteries. Some minor focal renal
artery irregularities attributed to minor spasm and/or edema were
noted immediately after RF energy delivery. None were consid-
ered flow limiting at procedure termination. Of the short-term
follow-up angiography performed in the first 20 patients, no
evidence of renal artery stenosis or abnormalities was noted in
treated arteries. In the 81 patients with 6-month magnetic
resonance angiography, computed tomography angiography, or
duplex evaluation, no irregularities or stenoses at any treatment
site were identified that were not present on pretreatment
angiography. One patient had a 6-month postprocedure com-
puted tomography angiography that identified progression of a
preexisting renal artery stenosis in the proximal portion of the
renal artery. This stenosis was successfully stented; the location
of the stenosis was quite proximal and well away from sites of
RF energy application.
Renal Function
During the first year of follow-up, eGFR remained stable,
with a change at 1, 3, 6, and 12 months of0.1 mL/min (95%
CI: 2.8 to 3.0; N112), 1.6 mL/min (95% CI: 4.3 to
1.1; N102), 0.1 mL/min (95% CI: 2.9 to 2.8; N87),
and 2.9 mL/min (95% CI: 6.2 to 0.3; N64), respec-
tively. eGFR data were only available on 10 patients at 2
years. In these 10 patients, eGFR changed by 16.0 mL/min
per 1.73 m2 at 24 months postprocedure. Five of these 10
patients had spironolactone or other diuretic added after the
first year of follow-up. In patients without newly added
spironolactone or other diuretic, eGFR changed 7.8 mL/
min per 1.73 m2 for an annualized change of 3.9 mL/min
per 1.73 m2. In no cases did serum creatinine double, the
patient develop class IV chronic kidney disease (15 to 29
mL/min per 1.73 m2), or the patient require dialysis.
Postural Hypotension and Edema
No patients reported symptomatic orthostatic hypotension.
Six patients reported transient dizziness, spread across the
entirety of the study period; no patients had any loss of
consciousness. Three patients reported pitting edema, which
was considered to be related to medication adjustment. This
responded to conservative care, use of diuretics, and/or
reduction in minoxidil dose.
Pain
Bilateral flank pain was reported by a single patient.
Extensive diagnostic evaluation did not identify a specific
cause for this pain. It did respond to ibuprofen over a
number of months but eventually completely resolved.
Three other patients reported intermittent or transient flank
or kidney pain; all resolved with or without analgesic
intervention.
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Death
Two patients died within the follow-up period postprocedure.
Neither death was considered by the study investigator or
Data Safety Monitoring Board to be related to the device or
the procedure. The first patient had known coronary artery
disease and died from a myocardial infarction. Clopidogrel
had been stopped after an episode of reversible cerebral
ischemia, which was thought to have occurred secondary to
atrial fibrillation with rapid ventricular response. The second
patient was a 61-year–old female with gastrointestinal dis-
ease and coronary artery bypass grafting who was thought to
have had sudden death.
Discussion
The present analysis has found that the initial reported BP
reduction out to 12 months postrenal sympathetic denervation
procedure has now been observed to persist out to 24 months
of follow-up postprocedure. Furthermore, this larger cohort
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Figure 1. A, Mean systolic and diastolic BP
changes after renal sympathetic denervation
procedure over 24-months of follow-up. Error
bars represent 95% CIs. B, Mean systolic
and diastolic BP changes after renal sympa-
thetic denervation procedure over 24 months
after censoring for medication increases post-
procedure. Error bars represent 95% CIs. C,
Mean systolic and diastolic BP changes after
renal sympathetic denervation procedure over
24 months for only the 18 patients with
24-month follow-up. The baseline BP among
the 18 patients followed for 2 years was 173/
9718/16 mmHg. Error bars represent 95% CIs.
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of denervated patients followed for a longer time period
appeared to experience few, if any, adverse effects that could
be attributed to the RF energy application.
It is worth remembering that these large and persistent BP
reductions occurred in patients who, by definition, were
refractory to standard medical therapies. Among this cohort,
92% of patients had a reduction in systolic BP.
The persistence of overall BP lowering out to 2 years is of
considerable clinical and pathophysiological relevance. The
findings of the present study, therefore, suggest that catheter-
based renal denervation results in initial sustained BP reduc-
tion to 24 months. If there is any reinnervation or counter-
regulatory mechanisms, they are not clinically relevant in this
time frame. This is particularly important given the dramatic
BP reduction compared with control reported in the Symplic-
ity HTN-2 Trial.9
A key issue in the clinical application of the procedure is in
prediction of which patients may best respond with regard to
falls in their BP. Although a relatively small cohort of
patients, it was of interest to perform multivariate analysis to
determine independent predictors of BP reductions. It was of
interest that, among baseline variables, only elevated BP and
use of central sympatholytics were predictors. Although the
former is intuitive, the latter does not appear to be so
biologically plausible. With an underlying 90% response rate
in conjunction with the low observed morbidity and the
reasonable cost of the procedure, it is improbable that a
screening demographic or test could be developed that might
be of any clinical value. The search for a screening test to
identify those few patients for which BP is not related to the
sympathorenal axis may principally have scientific value.
The magnitude of BP lowering postprocedure at 24 months
is no less than and appears to be numerically greater than that
observed at 12 months. It is, therefore, of interest to speculate
as to what may be driving this persistence of BP-lowering
effect postprocedure. This may represent a predominant
alteration in afferent signaling induced by the renal denerva-
tion procedure with a resetting of central sympathetic out-
flow, as demonstrated previously.12 This may be associated
with a resetting of the baroreflex around a lower homeostatic
set point. Vascular remodeling may have been reversed over
the 24-month period, with that reversal sustained postproce-
dure. Whatever the mechanism, this appears to override any
functional reinnervation that may be occurring postprocedure.
However, further follow-up of this cohort is required beyond
this time point to ascertain the status of BP lowering over an
even longer time, as well implications regarding the need for
repeat procedure(s).
The other important observation relates to renal function.
Clearly, elevated BP is a major determinant of decline in
renal function; BP lowering will have renoprotective effects.
Bakris et al13 have published a meta-analysis on expected
1-year eGFR decline based on starting systolic BP. The
decline in renal function observed in this 24-month follow-up
analysis is less than would be predicted based on the BP
response achieved, especially so over the first 12 months
postprocedure before the introduction of diuretics, which may
worsen renal function. Therefore, this suggests that there may
be an intrinsic beneficial effect of the procedure on the kidney
to maintain renal function, which is greater than that achieved
via BP reduction alone. Clearly, these findings can only be
considered hypothesis generating, however, because we do
not have a control group in this study, and comparisons are
based entirely on natural history studies from noncontempo-
raneous cohorts.13 Nonetheless, it is interesting to speculate
mechanistically as to why this may be occurring. In particu-
lar, sympathetic nerves drive release of a number of key
hormones regulating renal perfusion and glomerular filtra-
tion, including renin and adenosine. Blockade of renin has
been documented as part of neurohormonal profiling postpro-
cedure in this study.12 Blockade of adenosine (in particular,
A1 receptors in the kidney) has been shown to maintain
glomerular filtration while improving renal blood flow.12
Thus, renal sympathetic denervation theoretically (with some
supporting data from this analysis) would appear to slow the
BP- and time-related decline in eGFR in the hypertension
setting.
The other important observation from this extended
follow-up of renal denervation patients was the ongoing
safety observed within the study. In this report, a larger cohort
of patients is exposed to a longer period of postprocedure
follow-up without any major safety signals emerging. In
particular, in the cohort of 81 patients with 6-month
follow-up imaging, no cases of major de novo renal artery
stenosis have occurred, and only 1 case of progression of an
existing stenosis is described. Even with that single case, it
cannot be determined whether this was specifically related to
the interventional procedure or natural progression of a
baseline stenosis. No cases of renal artery aneurysm and no
cases with cholesterol emboli were documented in this series.
Furthermore, no late clinical sequelae (out to 2 years) could
be attributed to development of renal artery stenosis.
Aldosterone antagonists, such as spironolactone, have been
proposed for patients failing to attain target BP. It should be
noted that, in this cohort, 22% of the patients were already
38% 39%
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Figure 2. Distribution of office systolic BP in patients at base-
line, 12 months, and 24 months.
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taking spironolactone at baseline, yet failing to attain target.
The presence of the aldosterone blocker did not alter the
response to renal denervation. Baroreceptor stimulation, to
reduce baroreceptor reflex, has been explored as a treatment
for resistant hypertension. Comparisons with baroreceptor
stimulation are foiled by the inherently different morbidity
and cost of catheter-based renal denervation from a more
invasive surgical procedure requiring implantation of a per-
manent foreign body.
Limitations
As with the initial published report regarding this procedure,
this extended analysis has a number of important limitations.
There is no control group with which to make comparisons
regarding BP and eGFR responses over time. Therefore,
factors such as regression to the mean and Hawthorne effect
need to be considered in the interpretation of these results.
This limitation has been recently addressed in a prospective,
randomized control clinical trial (Symplicity HTN-2) that has
recruited similar patients and then randomly assigned them to
immediate or delayed (6-month) procedure to allow for such
comparisons.9 In addition, only relatively small numbers of
patients have reached the 24-month follow-up time point.
However, the consistency of the BP reductions achieved at
the differing time points postprocedure would suggest that the
present findings would be unlikely to differ greatly with
larger numbers reaching each follow-up time point.
Finally, modification of background antihypertensive drug
regimens was permitted in this study, although strongly
discouraged, especially over the first 12 months of follow-up.
As shown, there appeared to be little impact on BP reductions
when patients receiving increased medications were cen-
sored. However, there may have been an impact on eGFR
beyond the first 12 months postprocedure with increased use
of agents such as spironolactone and other diuretics.
In conclusion, this report, describing the prolonged renal
denervation experience out to 2 years, demonstrates durable
BP lowering over this period, in an extended cohort of
patients in whom the procedure was safely applied. There-
fore, renal sympathetic denervation appears to be a poten-
tially useful option for patients with refractory hypertension
with an expectation of persistent lowering of BP postproce-
dure. Randomized, controlled clinical trials are required to
confirm this initial proof-of-concept experience; the Symplic-
ity HTN-2 Trial9 has addressed this issue in such a manner.
Perspectives
A major issue with the renal denervation procedure is the
question mark over its durability, given the potential for
sympathetic nerves to regrow after damage to them. This
analysis demonstrates that significant postprocedure office
BP reductions were achieved by the renal denervation proce-
dure and sustained out to 24 months in this group of resistant
hypertensive patients. Thus, BP reductions, initially observed
out to 12 months, appear to persist to24 months, suggesting
durability of the denervation. The procedure itself was well
tolerated and generally safe; there were no periprocedural or
late adverse events associated with the application of RF
energy in this setting. Therefore, despite the potential for
nerve regrowth and reinnervation, there appeared to be little
if any impact on the functional (ie, BP-lowering) benefit of
the renal denervation procedure, at least out to 24 months.
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